FindTrial
Sign In

Chiglitazar sodium

DRUG3 trials

Sponsors

Yanbing Li, Yufan Wang, Second Xiangya Hospital of Central South University

Conditions

128 Patients Were Randomly Assigned 1:1Changes in HbA1C From Baseline at 18 Weeks of TreatmentDiabetesEfficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM PatientsInvestigatorInitiate TrialMetformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic EffectMetformin and Insulin Glargine Combined With Chiglitazar Sodium Tablets 48mg/ Day GroupMetformin and Insulin Glargine Combined With Placebo Group

Unknown Phase

Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes
NCT06007014
Yanbing Li128 Patients Were Randomly Assigned 1:1, Changes in HbA1C From Baseline at 18 Weeks of Treatment, Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients +4
Start: 2023-10-31End: 2025-12-30Target: 128Updated: 2023-09-13
A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM)
NCT06191328
Yufan WangDiabetes
Start: 2024-01-31End: 2025-12-30Target: 40Updated: 2024-01-05
Evaluation of Chiglitazar Sodium With Lifestyle Intervention for Reversing Prediabetes
Not yet recruitingNCT07558525
Second Xiangya Hospital of Central South UniversityPrediabetes
Start: 2026-04-18End: 2029-12-31Target: 472Updated: 2026-04-30